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Synthesis of Cisplatin & biological testing of the complex, compared to Triplatin (BBR3464)
Heba Dawood, Dr. Nicholas Farrell
Abstract
Two chemotherapeutic drugs were studied; one of them is 
Cisplatin that is currently used to fight cancer and the other is 
Triplatin (BBR3464) that was developed by Dr. Farrell. Cisplatin 
was synthesized and many different experiments were conducted 
such as: Recrystallization, Infrared Spectroscopy, UV-VIS, Melting 
Point, and Fluorescence experiment. After synthesizing the drug, it 
was tested in biology lab; we tested the effects of the drug on 
ovary cancer cells and its ability to kill cancer cells. A Cisplatin 
MTT ASSAY experiment was done and another MTT for Triplatin 
was done. Results from both of the experiments were compared 
and it was concluded that Triplatin is able to kill cancer cells more 
effectively and at lower concentrations than Cisplatin. 
Introduction
Cisplatin is an anti-cancer drug that is currently being used to 
treat cancer patients. It binds to DNA, bends it and changes the 
shape of it. However, it has some side effects such as 
Nephrotoxicity. Therefore, there is a need to develop other drugs
Triplatin (BBR3464) is a drug developed by Dr. Farrell to treat 
cancer; such as ovary cancer, colon cancer, lung cancer. The drug
reached Phase II human clinical trials with evidence of activity -
some patients were given three years of extra life. Side effects 
were not like Cisplatin and dose limiting toxicity (DLT) was 
diarrhea and extreme tiredness.
Many experiments were conducted:
For Cisplatin: Synthesis, Filteration, Elemental Analysis, Infrared, 
Spectroscopy (IR), UV-VIS, Melting Point and Fluorescence  
Experiment)
Then, biological testing for Cisplatin and Triplatin; (Cisplatin 
MTT ASSAY experiment MTT  ASSAY for Triplatin)
Methods for MTT ASSAY:
•1st day: change cell’s media, count cells, do the calculations, 
incubate cells for 24 hours
•2nd day: prepare the drug samples, give them to cells, incubate for 
72 hours
•Lastly; give the cells the MTT compound, wait 3 hours, then 
solubilization solution.
Results/Discussion
Cisplatin-IC50=1.77μM
Triplatin (BBR3464)-IC50=0.76µM
These results show that it takes less amount of Triplatin to kill 
cancer cells than Cisplatin; we only need 0.76µM of Triplatin to 
kill about 50% of the cancer cells 
Conclusion
Cisplatin is a good chemotherapeutic drug but it has side effects 
and therefore Dr. Farrell developed a new chemotherapeutic drug 
that is Triplatin. Also, Killing cancer cells using Triplatin requires 
only a small amount of it compared to Cisplatin
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Comparison on the amount needed to kill specific % of cancer cells 
between Triplatin (Left) and Cisplatin (Right)
Key: Dark color= cancer cells      Clear= no cancer cells
Different concentrations needed for specific % Inhibition
When it is heated; the double stranded DNA becomes a single stranded 
DNA. The temperature of the melting point at which that occurs is related 
to the drug that is used
